NZYM B Novozymes A/S Class B

Transaktioner i forbindelse med Novozymes’ aktietilbagekøbsprogram

Transaktioner i forbindelse med Novozymes’ aktietilbagekøbsprogram

Læs venligst hele meddelelsen i vedhæftede fil

Vedhæftet fil

EN
16/03/2020

Underlying

NZYM BNovozymes A/S Class B

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Novozymes A/S Class B

 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

2030 financial targets announced: Organic sales growth acceleration, m...

2030 financial targets announced: Organic sales growth acceleration, margin expansion and ROIC improvement COPENHAGEN, Denmark - August 20, 2025. Novonesis today announces its ‘GROW’ strategy and long-term targets for the strategy period until 2030 focusing on an acceleration of the core business and significant re-investments to secure long-term growth. By 2030, the company expects to deliver an organic sales CAGR of 6-9%, an adjusted EBITDA margin of ~39% and an adjusted ROIC excl. goodwill of ~16%. Novonesis is well positioned to continue to drive strong performance in biosolutions. The...

11h / 24m 1 EN
 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

2030 financial targets announced: Organic sales growth acceleration, m...

2030 financial targets announced: Organic sales growth acceleration, margin expansion and ROIC improvement Novonesis today announces its ‘GROW’ strategy and long-term targets for the strategy period until 2030 focusing on an acceleration of the core business and significant re-investments to secure long-term growth. By 2030, the company expects to deliver an organic sales CAGR of 6-9%, an adjusted EBITDA margin of ~39% and an adjusted ROIC excl. goodwill of ~16%. Novonesis is well positioned to continue to drive strong performance in biosolutions. The company is present across multiple end...

13h / 14m 1 EN
 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Major shareholder announcement

Major shareholder announcement Please read the full announcement in PDF. Attachments

July 21, 2025 1 EN
 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Biosolutions could create more than 600,000 jobs and unlock hundreds o...

Biosolutions could create more than 600,000 jobs and unlock hundreds of billions in growth for Europe Biosolutions could create more than 600,000 jobs and unlock hundreds of billions in growth for Europe A new report reveals that biosolutions could generate EUR 133 billion in economic gains and create over 600,000 jobs across all of Europe by 2035. But without urgent policy leadership and better regulation, Europe risks becoming the world’s best lab for solutions that scale elsewhere. Copenhagen, Denmark – 7 July 2025: Europe is on the verge of a job and growth boom if bio...

July 7, 2025 1 EN
 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Transactions under Novonesis’ share buyback program

Transactions under Novonesis’ share buyback program Novonesis has now completed the announced share buyback program of B shares worth up to EUR 100 million (DKK 746 million) in total during 2025. As of June 27th, 2025, Novonesis has purchased an accumulated  1,729,099 shares with a transaction value of DKK 745,2 million under the share buyback program announced by Novonesis in Company announcement No. 3, 2025 and initiated on March 5, 2025. Please read the full announcement in PDF. Attachment

June 30, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch